Additional treatments for early SARS-CoV-2 infection are needed. Metformin, ivermectin, and fluvoxamine have limited evidence of efficacy in this context. New research findings are summarized in a short video.
This content requires an NEJM.org account. Create a free account now. Already have an account? Sign in .
Quick Take Free Preview